{{item.CompanyName | formatName}}{{item.CurrentPrice.Amount | currency: ""}} : {{item.Change.Amount | number:2 }} ({{item.PercentChange.Value | percentChange | customCurrency: "" | trimValue}}%)

Editor's Choice

5 FREE Investing Reports That You Can Download Right Now!

HSBC Threatens To Redomicile Citing Regulatory Pressure

HSBC admits naughtiness but considers running away from home, says Kevin Godbold.

Premium Research: Is Boohoo.com The Next ASOS?

Or has the growth prospects of these two UK fashion companies been overstated?

The Tesco Revival Was Fun: Now The Hard Work Starts

Dave Lewis has made a canny start at TSCO but he has a long journey ahead of him, says Harvey Jones

Why Royal Dutch Shell Has Never Looked More Attractive

With earnings down and earning potential up, RDSB looks good for the long haul.

9.2 Billion Reasons To Buy Rolls-Royce, Cobham, GKN, easyJet & International Consolidated Airlines

Royston Wild explains why these five stocks are set to head higher.

Should You Sell Petrofac, Shire And Standard Chartered?

Do more problems lie ahead for PFC, Shire and STAN?

Will HSBC Deliver Stellar Returns Following Citigroup’s Super Earnings Report?

VIDEO: One Fool puts HSBC Holdings under the spotlight.

Why Over-Diversifying Can Cost Us Dearly

Taking the principle of portfolio diversification too far can ruin your financial future, says Kevin Godbold.

Why I Don’t Like BP And Royal Dutch Shell For The Long Term

VIDEO: One Fool takes a closer look at BP and RDSB.

Profit From The Biotech Boom With Vectura, Hikma And Indivior

VEC, HIK and INDV are three top plays on the biotech boom.

Your browser (Internet Explorer 8 or older) is out of date. It has known security flaws and may not display all features of this and other websites. We recommend updating to Google Chrome.